Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC

Lidia Ruiz, Joan Romeu, Javier Martínez-Picado, Jean Claude Schmit, Anne Mieke Vandamme, Montserrat Balagué, Cecilia Cabrera, Teresa Puig, Cristina Tural, Antònia Segura, Guillem Sirera, Erik De Clercq, Bonaventura Clotet

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)

Abstract

Objective: To evaluate the immunological and virological efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) and a double (ZDV+3TC) combination therapy in patients previously treated with ZDV plus ddC. Design: A 6-month follow-up open-label randomized study was undertaken in 46 HIV-1-infected patients previously treated for at least 6 months with ZDV plus ddC, who were allocated to receive either ZDV/ddC/3TC (n = 15) or ZDV/3TC (n = 15) or to continue with the ZDV/ddC regimen (control group; n = 16). Methods: Changes in CD4+ cell counts and plasma viral load (VL) were analysed with analysis of variance. Sequencing of the reverse transcriptase gene was performed in a subset of 3TC-treated patients. Results: Mean CD4+ cell counts increased significantly above baseline in both 3TC regimens whereas counts decreased in the control group. Significant plasma VL reduction was achieved in both 3TC combination therapy groups at weeks 4 and 24 compared with the control group. Coexistence of mutations conferring resistance to ZDV and 3TC were found in patients from both 3TC treatment groups. Conclusions: Both therapy strategies, switching ddC to 3TC or adding 3TC, significantly improved the virological and immunological efficacy compared with continuing ZDV/ddC. Our results support the use of 3TC in patients previously treated with the ZDV/ddC combination.
Original languageEnglish
JournalAIDS
Volume10
Issue number14
DOIs
Publication statusPublished - 1 Jan 1996

Keywords

  • Antiretroviral therapy
  • Lamivudine
  • Triple combination therapy
  • Viral load
  • Zalcitabine
  • Zidovudine

Fingerprint

Dive into the research topics of 'Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC'. Together they form a unique fingerprint.

Cite this